CVS wins a major CalPERS deal as Caremark replaces OptumRx, backed by $250M in performance guarantees and drug cost controls.

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

The contract, though sizable, is likely immaterial to CVS’ earnings. But it moves the company in a positive direction as it ...

The California Public Employees’ Retirement System (CalPERS) has a new pharmacy benefits contract with CVS Caremark, the ...

CVS is set to drop Zepbound as a medicine, but will continue to carry other popular weight loss drugs instead.

CVS Health’s Caremark business signed a new pharmacy benefits contract with the California Public Employees’ Retirement ...

CVS Health's pharmacy benefit manager unit must pay the U.S. government $95 million after a federal judge found it overcharged Medicare for prescription drugs.

As of July 1, CVS dropped Zepbound from preferred coverage for those covered by its pharmacy benefit manager, Caremark. Novo Nordisk A/S's Wegovy, a semiglutide injectable medicine, is now the primary ...

CVS Caremark has removed coverage of Zepbound, a GLP-1 weight-loss drug, citing pricing concerns and shifting payer dynamics that are reshaping how weight-loss treatments are covered under insurance ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

CVS Health has secured a major healthcare deal, winning a multi-year pharmacy benefits contract with CalPERS, outbidding rival UnitedHealth. The deal marks a significant win for CVS's Caremark unit ...

Pharmacy benefit manager CVS Caremark decided to replace Zepbound with Wegovy for use in weight loss starting July 1, despite Zepbound users having more weight loss success.